Angel-backed, late-stage pharmaceutical company Dipexium Pharmaceuticals has gone public. The company priced its IPO at $12 per share, the low end of its expected range, and now trades on the NASDAQ under the symbol DPRX. Dipexium's main product is Locilex, a topical antibiotic chemically synthesized from the skin of the African Clawed Frog that targets mild infections of diabetic foot ulcers. The company has raised several rounds of funding from angel investors totaling $6.9 million. Shares closed at $14.04 on their debut, up 17%.